RECENT ADVANCES IN RADIATION BIOLOGY.

E. L. Powers

Abstract:

What problem does this paper attempt to address?

Pre-existing sleep problems as a predictor of post-acute sequelae of COVID-19

Claudia Schilling,Alexandra Nieters,Michael Schredl,Raphael S Peter,Dietrich Rothenbacher,Stefan O Brockmann,Siri Göpel,Gerhard Kindle,Uta Merle,Jürgen M Steinacker,Winfried Kern,Epidemiology of Long COVID (EPILOC) Phase I study group,Dietrich August,Christoph Bauer,Benedict Blankenhorn,Ulrike Bopp-Haas,Stefanie Bunk,Peter Deibert,Armin Dietz,Birgit Friedmann-Bette,Roland Giesen,Veronika Götz,Sylvia Grote,Beate Grüner,Alexandra Junginger,Oliver Kappert,Johannes Kirsten,Hans-Georg Kräusslich,Anne Kühn,Nisar P Malek,Barbara Müller,Andreas Niess,Stefanie Pfau,Isolde Piechotowski,Siegbert Rieg,Sibylle Röttele,Jana Schellenberg,Chantal Schröder,Rainer Schwertz,Monika Spannenkrebs,Gabriele Wagner,Birgit Walter-Frank,Kersten Wolfers

DOI: https://doi.org/10.1111/jsr.13949

Abstract:Several months after COVID-19 many individuals still report persisting symptoms, the so-called 'post-COVID-19 syndrome'. An immunological dysfunction is one of the main pathophysiological hypotheses. As sleep is central to the functioning of the immune system, we investigated whether self-reported pre-existing sleep disturbance might be an independent risk factor for the development of post-COVID-19 syndrome. A total of 11,710 participants of a cross-sectional survey (all tested positive for severe acute respiratory syndrome coronavirus-2) were classified into probable post-COVID-19 syndrome, an intermediate group, and unaffected participants at an average of 8.5 months after infection. The case definition was based on newly occurring symptoms of at least moderate severity and ≥20% reduction in health status and/or working capacity. Unadjusted and adjusted odds ratios were calculated to investigate the association between pre-existing sleep disturbances and subsequent development of post-COVID-19 syndrome while controlling for a variety of demographic, lifestyle, and health factors. Pre-existing sleep disturbances were found to be an independent predictor of subsequent probable post-COVID-19 syndrome (adjusted odds ratio 2.7, 95% confidence interval 2.27-3.24). Sleep disturbances as part of the post-COVID-19 syndrome were reported by more than half of the participants and appeared to be a new symptom and to occur independent of a mood disorder in most cases. Recognition of disturbed sleep as an important risk factor for post-COVID-19 syndrome should promote improved clinical management of sleep disorders in the context of COVID-19. Further, it may stimulate further research on the effect of improving sleep on the prognosis of COVID-19 long-term sequelae and other post-viral conditions.
Attributes and predictors of long COVID

Carole H. Sudre,Benjamin Murray,Thomas Varsavsky,Mark S. Graham,Rose S. Penfold,Ruth C. Bowyer,Joan Capdevila Pujol,Kerstin Klaser,Michela Antonelli,Liane S. Canas,Erika Molteni,Marc Modat,M. Jorge Cardoso,Anna May,Sajaysurya Ganesh,Richard Davies,Long H. Nguyen,David A. Drew,Christina M. Astley,Amit D. Joshi,Jordi Merino,Neli Tsereteli,Tove Fall,Maria F. Gomez,Emma L. Duncan,Cristina Menni,Frances M. K. Williams,Paul W. Franks,Andrew T. Chan,Jonathan Wolf,Sebastien Ourselin,Tim Spector,Claire J. Steves

DOI: https://doi.org/10.1038/s41591-021-01292-y

IF: 82.9

2021-03-10

Nature Medicine

Abstract:Reports of long-lasting coronavirus disease 2019 (COVID-19) symptoms, the so-called 'long COVID', are rising but little is known about prevalence, risk factors or whether it is possible to predict a protracted course early in the disease. We analyzed data from 4,182 incident cases of COVID-19 in which individuals self-reported their symptoms prospectively in the COVID Symptom Study app<sup><a href="/articles/s41591-021-01292-y#ref-CR1">1</a></sup>. A total of 558 (13.3%) participants reported symptoms lasting ≥28 days, 189 (4.5%) for ≥8 weeks and 95 (2.3%) for ≥12 weeks. Long COVID was characterized by symptoms of fatigue, headache, dyspnea and anosmia and was more likely with increasing age and body mass index and female sex. Experiencing more than five symptoms during the first week of illness was associated with long COVID (odds ratio = 3.53 (2.76–4.50)). A simple model to distinguish between short COVID and long COVID at 7 days (total sample size, <i>n</i> = 2,149) showed an area under the curve of the receiver operating characteristic curve of 76%, with replication in an independent sample of 2,472 individuals who were positive for severe acute respiratory syndrome coronavirus 2. This model could be used to identify individuals at risk of long COVID for trials of prevention or treatment and to plan education and rehabilitation services.

biochemistry & molecular biology,cell biology,medicine, research & experimental
Cytotoxic cardenolides from woods of Euonymus alata.

Susumu Kitanaka,M. Takido,Kazutoshi Mizoue,Shiro Nakaike

DOI: https://doi.org/10.1248/CPB.44.615

1996-03-15

Chemical and Pharmaceutical Bulletin

Abstract:Three cytotoxic cardenolides, acovenosigenin A 3-O-alpha-L-ramnopyranoside (1), euonymoside A (2) and euonymusoside A (3), were isolated from the woods of Euonymus alata (Celastraceae). The chemical structure of a new cardenolide, euonymusoside A (3) has been elucidated on the basis of extensive spectral analysis and enzymic hydrolysis to be acovenosigenin A (1 beta, 3 beta, 14 beta-trihydroxy-5 beta-cardenolide) 3-O-beta-D-glucopyranosyl (1-->6)-beta-D-glucopyranosyl(1-->4)-alpha-L-rhamnopyranoside. All three showed potent cytotoxic activity against some neoplastic cell lines.
Characterizing long COVID in an international cohort: 7 months of symptoms and their impact

Hannah E. Davis,Gina S. Assaf,Lisa McCorkell,Hannah Wei,Ryan J. Low,Yochai Re'em,Signe Redfield,Jared P. Austin,Athena Akrami

DOI: https://doi.org/10.1016/j.eclinm.2021.101019

IF: 15.1

2021-08-01

EClinicalMedicine

Abstract:BackgroundA significant number of patients with COVID-19 experience prolonged symptoms, known as Long COVID. Few systematic studies have investigated this population, particularly in outpatient settings. Hence, relatively little is known about symptom makeup and severity, expected clinical course, impact on daily functioning, and return to baseline health.MethodsWe conducted an online survey of people with suspected and confirmed COVID-19, distributed via COVID-19 support groups (e.g. Body Politic, Long COVID Support Group, Long Haul COVID Fighters) and social media (e.g. Twitter, Facebook). Data were collected from September 6, 2020 to November 25, 2020. We analyzed responses from 3762 participants with confirmed (diagnostic/antibody positive; 1020) or suspected (diagnostic/antibody negative or untested; 2742) COVID-19, from 56 countries, with illness lasting over 28 days and onset prior to June 2020. We estimated the prevalence of 203 symptoms in 10 organ systems and traced 66 symptoms over seven months. We measured the impact on life, work, and return to baseline health.FindingsFor the majority of respondents (>91%), the time to recovery exceeded 35 weeks. During their illness, participants experienced an average of 55.9+/- 25.5 (mean+/-STD) symptoms, across an average of 9.1 organ systems. The most frequent symptoms after month 6 were fatigue, post-exertional malaise, and cognitive dysfunction. Symptoms varied in their prevalence over time, and we identified three symptom clusters, each with a characteristic temporal profile. 85.9% of participants (95% CI, 84.8% to 87.0%) experienced relapses, primarily triggered by exercise, physical or mental activity, and stress. 86.7% (85.6% to 92.5%) of unrecovered respondents were experiencing fatigue at the time of survey, compared to 44.7% (38.5% to 50.5%) of recovered respondents. 1700 respondents (45.2%) required a reduced work schedule compared to pre-illness, and an additional 839 (22.3%) were not working at the time of survey due to illness. Cognitive dysfunction or memory issues were common across all age groups (~88%). Except for loss of smell and taste, the prevalence and trajectory of all symptoms were similar between groups with confirmed and suspected COVID-19.InterpretationPatients with Long COVID report prolonged, multisystem involvement and significant disability. By seven months, many patients have not yet recovered (mainly from systemic and neurological/cognitive symptoms), have not returned to previous levels of work, and continue to experience significant symptom burden.FundingAll authors contributed to this work in a voluntary capacity. The cost of survey hosting (on Qualtrics) and publication fee was covered by AA's research grant (Wellcome Trust/Gatsby Charity via Sainsbury Wellcome center, UCL).
Sleep disorder syndromes of post-acute sequelae of SARS-CoV-2 (PASC) / Long Covid

Fernando M S Coelho,Richard Czuma,Amberly Ticotsky,Jason Maley,Janet M Mullington,Robert Joseph Thomas

DOI: https://doi.org/10.1016/j.sleep.2024.08.030

2024-08-29

Abstract:Introduction: COVID-19 infection has resulted in a high prevalence of a post-infectious syndrome, known as post-acute sequelae of SARS-CoV-2 (PASC) or "Long COVID". PASC is a heterogeneous disease with a high prevalence of sleep disturbances, varying from an insomnia disorder to excessive daytime sleepiness. Methods: Patients seen in the Covid Survivorship Program at the Beth Israel Deaconess Medical Center Boston, USA, were screened for sleep disorders as part of a comprehensive multi-system evaluation. Those who screened positive were referred for a comprehensive sleep evaluation in a dedicated COVID-19-Sleep clinic, followed by diagnostic sleep testing and treatment. This report summarizes patients who completed an American Academy of Sleep Medicine (AASM) accredited facility-based diagnostic evaluation. International Classification of Sleep Disorders 3rd Edition-Revised criteria were met for all diagnoses. Results: In 42 patients with PASC, five categories of sleep disorder syndromes were observed following a sleep clinic evaluation, including obstructive sleep apnea, chronic insomnia disorder, primary hypersomnia, REM behavior disorder (RBD), and new onset circadian phase delay. Seven patients met criteria for idiopathic hypersomnia, and two had narcolepsy type 2. RBD patients were infected in three different waves; circadian disturbance patients were all infected in the winter wave of 2020/21, and the primary hypersomnolence group occurred during all waves, predominantly the initial wave of 2020. A peculiar form of insomnia was a persistent loss of sleep regularity. Conclusions: Specific sleep symptoms/syndromes are reported in this select group of patients with PASC/Long Covid. As new onset sleep complaints are prevalent in PASC, we recommend a complete clinical and investigative sleep evaluation for persistent severe sleep symptoms following COVID-19 infection.
Symptoms and risk factors for long COVID in non-hospitalized adults

Anuradhaa Subramanian,Krishnarajah Nirantharakumar,Sarah Hughes,Puja Myles,Tim Williams,Krishna M. Gokhale,Tom Taverner,Joht Singh Chandan,Kirsty Brown,Nikita Simms-Williams,Anoop D. Shah,Megha Singh,Farah Kidy,Kelvin Okoth,Richard Hotham,Nasir Bashir,Neil Cockburn,Siang Ing Lee,Grace M. Turner,Georgios V. Gkoutos,Olalekan Lee Aiyegbusi,Christel McMullan,Alastair K. Denniston,Elizabeth Sapey,Janet M. Lord,David C. Wraith,Edward Leggett,Clare Iles,Tom Marshall,Malcolm J. Price,Steven Marwaha,Elin Haf Davies,Louise J. Jackson,Karen L. Matthews,Jenny Camaradou,Melanie Calvert,Shamil Haroon

DOI: https://doi.org/10.1038/s41591-022-01909-w

IF: 82.9

2022-07-26

Nature Medicine

Abstract:Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is associated with a range of persistent symptoms impacting everyday functioning, known as post-COVID-19 condition or long COVID. We undertook a retrospective matched cohort study using a UK-based primary care database, Clinical Practice Research Datalink Aurum, to determine symptoms that are associated with confirmed SARS-CoV-2 infection beyond 12 weeks in non-hospitalized adults and the risk factors associated with developing persistent symptoms. We selected 486,149 adults with confirmed SARS-CoV-2 infection and 1,944,580 propensity score-matched adults with no recorded evidence of SARS-CoV-2 infection. Outcomes included 115 individual symptoms, as well as long COVID, defined as a composite outcome of 33 symptoms by the World Health Organization clinical case definition. Cox proportional hazards models were used to estimate adjusted hazard ratios (aHRs) for the outcomes. A total of 62 symptoms were significantly associated with SARS-CoV-2 infection after 12 weeks. The largest aHRs were for anosmia (aHR 6.49, 95% CI 5.02–8.39), hair loss (3.99, 3.63–4.39), sneezing (2.77, 1.40–5.50), ejaculation difficulty (2.63, 1.61–4.28) and reduced libido (2.36, 1.61–3.47). Among the cohort of patients infected with SARS-CoV-2, risk factors for long COVID included female sex, belonging to an ethnic minority, socioeconomic deprivation, smoking, obesity and a wide range of comorbidities. The risk of developing long COVID was also found to be increased along a gradient of decreasing age. SARS-CoV-2 infection is associated with a plethora of symptoms that are associated with a range of sociodemographic and clinical risk factors.

biochemistry & molecular biology,cell biology,medicine, research & experimental
The association of insomnia with long COVID: An international collaborative study (ICOSS-II)

Si-Jing Chen,Charles M Morin,Hans Ivers,Yun Kwok Wing,Markku Partinen,Ilona Merikanto,Brigitte Holzinger,Colin A Espie,Luigi De Gennaro,Yves Dauvilliers,Frances Chung,Juliana Yordanova,Domagoj Vidović,Catia Reis,Giuseppe Plazzi,Thomas Penzel,Michael R Nadorff,Kentaro Matsui,Sergio Mota-Rolim,Damien Leger,Anne-Marie Landtblom,Maria Korman,Yuichi Inoue,Harald Hrubos-Strøm,Ngan Yin Chan,Adrijana Koscec Bjelajac,Christian Benedict,Bjørn Bjorvatn,Charles M. Morin,Colin A. Espie,Michael R. Nadorff

DOI: https://doi.org/10.1016/j.sleep.2023.09.034

IF: 4.842

2023-10-26

Sleep Medicine

Abstract:s Objective There is evidence of a strong association between insomnia and COVID-19, yet few studies have examined the relationship between insomnia and long COVID. This study aimed to investigate whether COVID-19 patients with pre-pandemic insomnia have a greater risk of developing long COVID and whether long COVID is in turn associated with higher incident rates of insomnia symptoms after infection. Methods Data were collected cross-sectionally (May–Dec 2021) as part of an international collaborative study involving participants from 16 countries. A total of 2311 participants (18–99 years old) with COVID-19 provided valid responses to a web-based survey about sleep, insomnia, and health-related variables. Log-binomial regression was used to assess bidirectional associations between insomnia and long COVID. Analyses were adjusted for age, sex, and health conditions, including sleep apnea, attention and memory problems, chronic fatigue, depression, and anxiety. Results COVID-19 patients with pre-pandemic insomnia showed a higher risk of developing long COVID than those without pre-pandemic insomnia (70.8% vs 51.4%; adjusted relative risk [RR]: 1.33, 95% confidence interval [CI]: 1.07–1.65). Among COVID-19 cases without pre-pandemic insomnia, the rates of incident insomnia symptoms after infection were 24.1% for short COVID cases and 60.6% for long COVID cases ( p < .001). Compared with short COVID cases, long COVID cases were associated with an increased risk of developing insomnia symptoms (adjusted RR: 2.00; 95% CI: 1.50–2.66). Conclusions The findings support a bidirectional relationship between insomnia and long COVID. These findings highlight the importance of addressing sleep and insomnia in the prevention and management of long COVID.

clinical neurology
Sleep and memory complaints in long COVID: an insight into clustered psychological phenotypes

Ricardo Titze-de-Almeida,Pedro Henrique Araújo Lacerda,Edson Pereira de Oliveira,Mariah Eduarda Ferreira de Oliveira,Yngrid Sallaberry Silva Vianna,Amanda Machado Costa,Eloísa Pereira dos Santos,Louise Marie Coelho Guérard,Matheus Augusto de Miranda Ferreira,Isabel Cristina Rodrigues dos Santos,Jéssica Daniele da Silva Gonçalves,Gabriel Ginani Ferreira,Simoneide Souza Titze-de-Almeida,Pedro Renato de Paula Brandão,Helena Eri Shimizu,Andrezza Paula Brito Silva,Raimundo Nonato Delgado-Rodrigues,

DOI: https://doi.org/10.7717/peerj.16669

IF: 3.061

2024-01-30

PeerJ

Abstract:This study evaluated clinical features of individuals with long COVID (5–8 months after diagnosis) who reported sleep and memory problems (62 cases) compared to those without (52 controls). Both groups had a similar mean age (41 vs. 39 years). Around 86% of the participants were non-hospitalized at the time of infection, and none of them were vaccinated at that point. Subsequently, both cases and controls received the vaccine; however, the vaccination rates differed significantly between the groups (30.7% vs. 51.0%). Cases and controls had similar rates of symptoms at acute COVID phase. However, cases were more likely to experience coryza, dyspnea, headache, and nausea/vomiting during long COVID. Regarding new-onset symptoms in long COVID, 12.9% of cases had dyspnea, and 14.5% experienced nausea/vomiting, whereas in the control group there were only 1.9% and 0.0%, respectively. Cases also had a significantly higher prevalence of persistent headache (22.6% vs. 7.7%), and dyspnea (12.9% vs. 0.0). In addition, cases also showed an increased rate of mental health complaints: disability in daily activities (45.2% vs. 9.6%; P < 0.001); concentration/sustained attention difficulties (74.2% vs. 9.6%; P < 0.001); anxiety–Generalized Anxiety Disorder 2-item scale (GAD-2) ≥ 3 (66.1% vs. 34.6%; P = 0.0013); and “post-COVID sadness” (82.3% vs. 40.4%; P < 0.001). We observed a significant correlation between sadness and anxiety in cases, which was not observed in controls (P=0.0212; Spearman correlation test). Furthermore, the frequency of concomitant sadness and anxiety was markedly higher in cases compared to controls (59.7% vs. 19.2%) ( P < 0.0001; Mann-Whitney test). These findings highlight a noteworthy association between sadness and anxiety specifically in cases. In conclusion, our data identified concurrent psychological phenotypes in individuals experiencing sleep and memory disturbances during long COVID. This strengthens the existing evidence that SARS-CoV-2 causes widespread brain pathology with interconnected phenotypic clusters. This finding highlights the need for comprehensive medical attention to address these complex issues, as well as major investments in testing strategies capable of preventing the development of long COVID sequelae, such as vaccination.

multidisciplinary sciences
Highly Sensitive Detection of Bisphenol A by NanoAptamer Assay with Truncated Aptamer.

Eun-Hee Lee,Hyun Jeong Lim,Sang-Don Lee,A. Son

DOI: https://doi.org/10.1021/acsami.7b02377

2017-04-20

Abstract:For the sensitive quantification of bisphenol A (BPA), we have developed NanoAptamer assay, which employs aptamer and complementary signaling DNA, a set of quantum dots (QD), and magnetic beads (MBs). Signaling DNA-QD655 was tethered to MB-QD565 via the aptamer. The affinity of the aptamer to BPA resulted in the release of the signaling DNA-QD655 from the complex and hence the corresponding decrease in the QD655 fluorescence measurement signal. Three new aptamers (23, 58, and 24-mer) were designed via truncation of the reference aptamer (73-mer). The sensitivity and selectivity of each aptamer for BPA detection via NanoAptamer assay were investigated. One of the truncated aptamers (24-mer) has shown a significantly better performance (limit of detection, LOD, 0.17 pg/mL) than the reference 73-mer aptamer (LOD, 570 pg/mL). It has also shown the best selectivity for BPA detection over BPA analogues (i.e., bisphenol B, bisphenol C, and diethylstilbestrol). It corresponded to a normalized fluorescence change of 33.7% at the environmentally relevant concentration of 1 ng/mL (1 ppb) BPA; however, the analogues remained unchanged (2.3-3.9%).
Prevalence and associations of insomnia after COVID-19 infection

Alexandra Kadl,Eric M Davis,Samuel F Oliver,Samuel A Lazoff,John Popovich,Amr A E Atya,Kyle B Enfield,Mark Quigg

DOI: https://doi.org/10.5664/jcsm.11420

2024-10-22

Abstract:Study objectives: Sleep disturbances in "long COVID" are common, but the associations between the severity of sleep problems and the severity of COVID infection are unclear. We evaluated the prevalence, persistence, comorbidities, and clinical effects of insomnia following recovery from acute COVID-19 infection in a COVID-specific clinic. Methods: Inpatients discharged after COVID infection and outpatients referred for persistent post-COVID symptoms were surveyed on insomnia severity (Insomnia Severity Index, ISI), other neuropsychological symptoms, cardiopulmonary symptoms and physiological functions (6 minute walk distance and others), and functional outcome and quality of life (QOL). Multivariable regression models evaluated the severity of ISI against independent variables. Results: A total of 280 patients met criteria at the initial visit. The prevalence of significant insomnia at the initial visit was 50% and 42% at the subsequent visit (obtained in 78 of the 280 patients). Lower age, female sex, non-white race, and non-Hispanic ethnicity were significantly associated with worse initial ISI scores. More severe symptoms of anxiety and depression were strong correlates with worse ISI scores. Interval improvements in insomnia severity correlated with improvements in anxiety and post-traumatic stress disorder (PTSD) scores. Physiological sequelae of infection did not correlate with insomnia at any stage. Conclusions: Initial and persistent insomnia is common in long COVID. Treatment for insomnia with the use of evidence based approaches (such as cognitive behavioral therapy for insomnia) may best suit this particular post-COVID symptom.
Histiocytosis X and renal insufficiency.

C. Materne,S. Porubský,J. Gerth,H. Gröne,G. Wolf

DOI: https://doi.org/10.1093/NDT/GFM299

2007-12-01

Abstract:Langerhans cell histiocytosis (LCH) is a rare disordershowing a wide spectrum of clinical manifestationsranging from single cutaneous lesions to multifocalsystemic disease [1,2]. The typical infiltration consistsof pathological monoclonal Langerhans cells togetherwith lymphocytes, eosinophilic granulocytes and non-dendritic histiocytes [3]. Langerhans cells are antigen-presenting cells with features of dendritic cells, stainingpositive for CD1a [4]. One of their original functions iscutaneous immunosurveillance. LCH is rare and theincidence in adults is 1–2 cases per million, with a meanage of 35 14 years, and is slightly more prevalent inmales [5,6]. Histological diagnosis is made if lightmicroscopic morphological characteristics of the dis-ease are found with positive staining for CD1a antigen[4,7]. In addition, Birbeck granules in the lesional cellthat are detected with electron microscopy are alsosuggestive of the disease [4,7]. Typical manifestationsof LCH in adults are central diabetes insipidus, bone,pulmonary, skin disease and dental involvement.We report a case of a patient with progressive renalinsufficiency due to multi-systemic manifestation ofLangerhans cell histiocytosis including involvement ofthe kidneys. Treatment of LCH with chemotherapyresulted in stabilization of renal function.CaseA 46-year-old male patient was admitted to ournephrology clinic in May 2006, with a 1-year historyof impaired renal function with moderate proteinuriaand glomerular erythrocyturia. In 1991, the patientwas successfully treated for fibrous alveolitis withprednisolone. Two years later, the patient developedcentral diabetes insipidus. In 1999, Histiocytosis X(Langerhans cell histiocytosis, LCH) was diagnosed ina skin biopsy obtained from an axillary erythema(histological findings: cellular infiltration of the epi-dermis with histiocytes, co-expression of S100 andCD1a; negativity for lymphocytic markers and KL-1;positive PG-M1; epitheliotropism; highly-positive toMiB1). In the follow-up, he also developed bilaterallyrelapsing therapy-resistant external otitis and swollencervical and submandibular lymph nodes. CT thoraxrevealed disseminated micronodular pulmonal opaci-ties. Skeletal scintigraphy showed a suspicious focus inthe proximal left tibia, and foci in the left mandible andleft mastoid could be localized. Thin-layer magneticresonance tomography of the sella turcica providedevidence for granuloma, with contrast enhancement inthe area of the hypophyseal stalk. An intravenousprednisolone therapy with 100mg was performed andthe cutaneous focus showed a rapid diminution.Therefore, methylprednisolone (60mg/day for 4weeks) and vinblastine (7mg/m
1136 Sleep Disorders in Children and Adolescents with Long COVID

Shikha Mistry,Samuel Rodgers-Melnick,Jennifer Murphy,David Miller,Amy Edwards,Sally Ibrahim

DOI: https://doi.org/10.1093/sleep/zsae067.01136

IF: 6.313

2024-04-20

SLEEP

Abstract:Abstract Introduction Recognition of Long COVID is increasing and sleep disturbances are common to this population. This study describes sleep disorders and associated comorbidities in youth with Long COVID. Methods This is a retrospective cross-sectional study of patients initially presenting to the Long COVID clinic. We examined the prevalence of sleep disturbances (SD) and compared those with and without SD in comorbidity and symptomatology. Single-factor regression analyses were used to explore the relationship between SD and patient well-being. Multi-factor regressions analyses with PROMIS SD score as the predictor and age as a continuous covariate were analyzed for the several response variables: child well-being, general fatigue, sleep/rest fatigue, cognitive-fatigue, total fatigue, anxiety, and depression scores. Results Of 250 patients: age ranged 3-24 years(mean 14.6± 3.4years), predominantly female(157/250;63%), white(202/81%);and non-Hispanic(204/250;82%). Patients with SD made up 26%(64/250): 28% circadian rhythm disorders, 31% insomnia, and 1.2% hypersomnia. Compared to the non-SD group, the SD group was more likely to report comorbidities: abdominal pain(52% vs37%, p=0.035), nausea(64% vs52% p=0.084), constipation(50% vs26% p< 0.001), anxiety(89% vs53% p< 0.001), depression (48% vs27% p=0.002), ADHD(27% vs27% p=0.008), headaches(88% vs67%, p=0.002), dizziness (83% vs52%, p< 0.001), POTS(28% vs16%, p=0.027), brain fog(47% vs29%, p=0.009), fatigue (95% vs77%, p=0.001), appetite loss(47% vs29%, p=0.007), and fever(47% vs72%, p=0.053). Using regression analyses, higher PROMIS SD scores negatively associated with child well-being scores (β2= -0.71±0.2; F2, 63=6.37, P< 0.001, R2=0.17), sleep/rest fatigue(β2=-0.51±0.26; F2, 63=5.81, P=0.004, R2=0.16), and total fatigue(β2=-0.65 ±0.2; F2, 63=8.05, P< 0.001, R2=0.20). No significant relationships were found with general/cognitive fatigue scores. Positive correlations found between PROMIS SD scores and anxiety and depression t-scores(β2= 0.26±0.10; F2, 63=3.08, P=0.05, R2=0.09; and β2=0.30±0.11; F2, 65=3.74, P=0.03, R2=0.11, respectively). Conclusion Sleep disorders are prevalent among youth with long-COVID, often coexisting with higher rates of physical, neurological, and psychological symptoms. Higher PROMIS SD scores predict lower child well-being, and higher mood disorder scores. While other factors likely impact long-COVID outcomes, sleep plays an integral role. These findings suggest that SD is a key factor in the overall health and mood of children with Long-COVID, emphasizing the need for integrated care approaches that address both sleep and psychological health. Support (if any)

neurosciences,clinical neurology
Studying the Effect of Long COVID-19 Infection on Sleep Quality Using Wearable Health Devices: Observational Study

Mario Mekhael,Chan Ho Lim,Abdel Hadi El Hajjar,Charbel Noujaim,Christopher Pottle,Noor Makan,Lilas Dagher,Yichi Zhang,Nour Chouman,Dan L Li,Tarek Ayoub,Nassir Marrouche

DOI: https://doi.org/10.2196/38000

IF: 7.076

2022-07-05

Journal of Medical Internet Research

Abstract:Background Patients with COVID-19 have increased sleep disturbances and decreased sleep quality during and after the infection. The current published literature focuses mainly on qualitative analyses based on surveys and subjective measurements rather than quantitative data. Objective In this paper, we assessed the long-term effects of COVID-19 through sleep patterns from continuous signals collected via wearable wristbands. Methods Patients with a history of COVID-19 were compared to a control arm of individuals who never had COVID-19. Baseline demographics were collected for each subject. Linear correlations among the mean duration of each sleep phase and the mean daily biometrics were performed. The average duration for each subject’s total sleep time and sleep phases per night was calculated and compared between the 2 groups. Results This study includes 122 patients with COVID-19 and 588 controls (N=710). Total sleep time was positively correlated with respiratory rate (RR) and oxygen saturation (SpO2). Increased awake sleep phase was correlated with increased heart rate, decreased RR, heart rate variability (HRV), and SpO2. Increased light sleep time was correlated with increased RR and SpO2 in the group with COVID-19. Deep sleep duration was correlated with decreased heart rate as well as increased RR and SpO2. When comparing different sleep phases, patients with long COVID-19 had decreased light sleep (244, SD 67 vs 258, SD 67; P=.003) and decreased deep sleep time (123, SD 66 vs 128, SD 58; P=.02). Conclusions Regardless of the demographic background and symptom levels, patients with a history of COVID-19 infection demonstrated altered sleep architecture when compared to matched controls. The sleep of patients with COVID-19 was characterized by decreased total sleep and deep sleep.

health care sciences & services,medical informatics
Sleep Disorders in Patients after COVID-19

M. A. Ahmet’yanov,L. I. Reikhert,O. A. Kicherova,D. M. Veeva,D. V. Makarova

DOI: https://doi.org/10.1007/s11055-022-01290-8

2022-09-14

Neuroscience and Behavioral Physiology

Abstract:Healthy sleep is required to ensure the body's homeostatic stability, the consistency of immunological reactions, and optimum functioning of the internal organs, the nervous system, and cognitive functions. Patterns of changes to the circadian rhythms have been studied in many diseases, though infection with SARS-CoV-2 is a new reality and the basic mechanisms of functioning of the body in this pathology require deeper investigation. Despite the difficulty of analytical investigations in pandemic conditions, experience of the diagnosis of COVID-19 has now been acquired and treatment algorithms have been developed for different clinical situations; vaccines have been developed. Least studied are questions of the long-term sequelae of COVID-19. At the same time, there are good grounds for suggesting that patients need long-term rehabilitation in the post-covid period of SARS-CoV-2, for reasons including damage to the nervous system. Analysis of publications – from descriptions of clinical cases to literature reviews – allows empirical experience to be accumulated, providing the opportunity for future identification of prognostic markers for the disease for effective prevention of long-term sequelae. The results of current prospective studies draw attention to the occurrence of dyssomnia and obstructive sleep apnea not only as a common consequence of coronavirus infection, but also as a factor significantly worsening the prognosis in the acute period of illness. It has repeatedly been shown that sleep deprivation has adverse influences on the body's resistance, including to SARS-CoV-2, and requires correction to improve prognoses in the acute and long-term periods of illness in COVID-19 patients.
Long COVID symptoms and sleep problems: a population-based study

Anna Letícia,Rosália Garcia Neves,Yohana Pereira Vieira,Tatiane Nogueira Gonzales,Melissa Marochi,Rodrigo Zopellaro Reis,Karla Pereira Machado,Suele Manjourany Silva Duro,Mirelle de Oliveira Saes

DOI: https://doi.org/10.1111/jsr.14327

2024-09-05

Abstract:To investigate the association between symptoms of long-term effects of coronavirus disease 2019 (long COVID) and sleep problems in a sample population from southern Brazil. This cross-sectional study used data from the SULcovid-19 survey, developed in the municipality of Rio Grande, RS, Brazil. The outcome, long COVID, was investigated through the presence of 18 symptoms, and the exposure variable was sleep problems. Poisson regression with robust adjustment for variance was used to estimate crude and adjusted prevalence ratios for the outcome-exposure relationship. Odds ratio was calculated through multinomial regression of the relationship between the number of symptoms of long COVID and sleep problems. Analyses were adjusted for sex, age, marital status, income, body mass index, smoking status, comorbidities, and hospital admission. A total of 2919 adults and older adults were interviewed. The prevalence of long COVID was 48.3% (95% confidence interval [CI] 46.5-50.1%) and sleep problems were reported by 41.2% of the sample (95% CI 39.4-43.0%). Individuals with sleep problems were more likely to exhibit altered sensitivity (prevalence ratio [PR] 3.27; 95% CI 1.96-5.45), nasal congestion (PR 2.75; 95% CI 1.53-4.94), musculoskeletal symptoms (PR 1.75; 95% CI 1.48-2.06), respiratory issues (PR 1.58; 95% CI 1.24-2.01), and one or more symptom of long COVID (PR 1.27; 95% CI 1.15-1.39). Approximately one-half of the population analysed had long COVID, and four of 10 reported experiencing sleep problems. In addition, the sample tended to have experienced a greater number of symptoms compared with those who reported to sleep well.
Long COVID prevalence and impact on quality of life 2 years after acute COVID-19

Yoonjung Kim,Sohyun Bae,Hyun-Ha Chang,Shin-Woo Kim

DOI: https://doi.org/10.1038/s41598-023-36995-4

IF: 4.6

2023-07-11

Scientific Reports

Abstract:Abstract There has been an increasing interest in the long-term impact of long COVID. However, only a few studies have investigated the clinical manifestations of long COVID 24 months after acute COVID infection. In this study, prospective online surveys were conducted in adults previously diagnosed with coronavirus disease 2019 (COVID-19) in South Korea between February 13 and March 13, 2020, at 6, 12, and 24 months after COVID-19. We investigated self-reported symptoms and the EuroQol-5-dimension index. Among 900 individuals enrolled initially, 150 completed all 3 surveys. After excluding the cases of COVID-19 reinfection, 132 individuals were included in the final analysis. Among the 132 participants, 94 (71.2%) experienced symptoms of long COVID. The most frequently reported symptoms were fatigue (34.8%), amnesia (30.3%), concentration difficulties (24.2%), insomnia (20.5%), and depression (19.7%). Notably, no significant differences were noted in the incidence of long COVID at 24 months in terms of the number of vaccinations received. Although the neuropsychiatric quality of life improved over time, it continued to affect 32.7% of participants. Symptoms of long COVID, particularly neuropsychiatric symptoms, tend to persist over time, and COVID-19 vaccination or the number of vaccinations received may not significantly affect the incidence of long COVID.

multidisciplinary sciences
1135 Predictors of Post-COVID Clinical and Cognitive Consequences

Danny Greig,Ruchi Rastogi,Teresa Diaz,Maria Tovar-Torres,Bradley Axelrod,Lili Zhao,M Safwan Badr,Susmita Chowdhuri

DOI: https://doi.org/10.1093/sleep/zsae067.01135

IF: 6.313

2024-04-20

SLEEP

Abstract:Abstract Introduction “Post-acute sequelae of SARS-COV-2 infection (PASC)” is a condition with a wide range of physical and mental health consequences that are present or persist four or more weeks after SARS-COV-2 infection. Fatigue is one of the most common PASC symptoms. It is not known whether underlying OSA and sleep disturbances may influence the persistence of chronic physical, mental health and neurocognitive dysfunction post-COVID. This pilot study will systematically examine whether sleep disturbances and severity of OSA comprise modifiable facets of PASC. Methods We prospectively collected sleep quality, sleepiness, quality of life (QoL) and neurocognitive data in patients with post-COVID fatigue (PASC) and OSA, and compared with control patients with OSA but without prior COVID infection. Questionnaires were administered at baseline and after 3 months to evaluate sleep disturbances, sleepiness, and general and disease specific QoL. Cognitive testing included Trail Making Test Part A and B, Paced Auditory Serial Addition Test (PASAT), Stroop Task, Digit Coding, Hopkins Verbal Learning Test-R (HVLT-R), Weschler Abbreviated Scale Intelligence II (WASI), Weschler Memory Scale IV (WSM), and Psychomotor Vigilance Test (PVT), respectively. 6-minute walk test and COVID-infection related medical data were also collected. Results Thus far, we have enrolled 26 total participants, 16 controls (13 males, 3 females; age: 65.4±11.7 years, BMI: 35.4±12.8 kg/m2, AHI: 49.2±34.6/hr, Education:14.4±3.0 years), and10 patients with PASC (7 males, 3 females; age: 59.3±12.8 years, BMI: 31.7±8.4 kg/m2, AHI: 44.2±33.6/hr, Education:16±2.3 years).Baseline data in controls vs. PASC patients are given as: FSS Total Score: 29.8±16.7 vs. 37.9±11.2, ESS: 8.6±4.7 vs. 8.5±5.6, PROMISE Sleep Disturbance Score: 20.2±10.1 vs. 22.9±11.2, 6-Minute Walk Test Total Distance Walked: 415.5±56.8 vs. 389.1±47.2 meters, FOSQ Total Score: 16.7±3.9 vs. 17.17±3.2, HVLTR Total Recall: 88.2±14.5 vs. 83.2±16.2, WMSIV Visual Reproduction Delayed Recall: 109.2±19.8 vs. 106.2±27.7, TMT-B: 94.2±21.1 vs. 93.0±25.6, Stroop Color-Word Score: 88.7±10.7 vs. 94.5±20.1, WASI-II FISQ4 Score: 97.6±11.2 vs. 96.2±17.2, PASAT Rate 2 Correct: 38.8±25.4% vs. 33.3±33.3%, PVT Mean Reaction Time: 319.2±65.2 vs. 324.7±149.5 ms. Conclusion Our study provides preliminary data on important clinical metrics in patients with post-COVID sequelae. Additional data will allow us to determine future targets for management of PASC. Support (if any) VHA RR&D # RX004396 (SPiRE)

neurosciences,clinical neurology
Sleep and Daytime Problems During the COVID-19 Pandemic and Effects of Coronavirus Infection, Confinement and Financial Suffering: a Multinational Survey Using a Harmonised Questionnaire

Markku Partinen,Brigitte Holzinger,Charles M. Morin,Colin Espie,Frances Chung,Thomas Penzel,Christian Benedict,Courtney J. Bolstad,Jonathan Cedernaes,Rachel Ngan Yin Chan,Yves Dauvilliers,Luigi De Gennaro,Fang Han,Yuichi Inoue,Kentaro Matsui,Damien Leger,Ana Suely Cunha,Ilona Merikanto,Sergio Mota-Rolim,Michael Nadorff,Giuseppe Plazzi,Jules Schneider,Mariusz Sieminski,Yun-Kwok Wing,Bjorn Bjorvatn

DOI: https://doi.org/10.1136/bmjopen-2021-050672

IF: 3.006

2021-01-01

BMJ Open

Abstract:Objectives Sleep is important for human health and well-being. No previous study has assessed whether the COVID-19 pandemic impacts sleep and daytime function across the globe. Methods This large-scale international survey used a harmonised questionnaire. Fourteen countries participated during the period of May-August 2020. Sleep and daytime problems (poor sleep quality, sleep onset and maintenance problems, nightmares, hypnotic use, fatigue and excessive sleepiness) occurring 'before' and 'during' the pandemic were investigated. In total, 25 484 people participated and 22 151 (86.9%) responded to the key parameters and were included. Effects of COVID-19, confinement and financial suffering were considered. In the fully adjusted logistic regression models, results (weighted and stratified by country) were adjusted for gender, age, marital status, educational level, ethnicity, presence of sleep problems before COVID-19 and severity of the COVID-19 pandemic in each country at the time of the survey. Results The responders were mostly women (64%) with a mean age 41.8 (SD 15.9) years (median 39, range 18-95). Altogether, 3.0% reported having had COVID-19; 42.2% reported having been in confinement; and 55.9% had suffered financially. All sleep and daytime problems worsened during the pandemic by about 10% or more. Also, some participants reported improvements in sleep and daytime function. For example, sleep quality worsened in about 20% of subjects and improved in about 5%. COVID-19 was particularly associated with poor sleep quality, early morning awakening and daytime sleepiness. Confinement was associated with poor sleep quality, problems falling asleep and decreased use of hypnotics. Financial suffering was associated with all sleep and daytime problems, including nightmares and fatigue, even in the fully adjusted logistic regression models. Conclusions Sleep problems, fatigue and excessive sleepiness increased significantly worldwide during the first phase of the COVID-19 pandemic. Problems were associated with confinement and especially with financial suffering.
The association between probable post‐COVID‐19 condition and sleep‐related parameters: a longitudinal study of non‐hospitalised patients

Diogo Gonçalves,Joana Pinto Costa,Susana Silva,Margarida Tavares,Henrique Barros,Paula Meireles

DOI: https://doi.org/10.1111/jsr.14215

2024-05-17

Journal of Sleep Research

Abstract:Summary The long‐term effects of severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection on sleep remain poorly known. We evaluated the association between probable post‐COVID‐19 condition and changes in sleep quality and quantity before and after SARS‐CoV‐2 infection in a consecutive sample of non‐hospitalized adults. Individuals were identified with SARS‐CoV‐2 infection in 2020 at the central laboratory of a tertiary hospital in Porto and followed as outpatients. We included patients diagnosed with SARS‐CoV‐2 infection ≥3 months before this evaluation, with no missing data on key variables (n = 2445). Participants completed a questionnaire that included sociodemographic, clinical, and infection‐related questions. We computed changes in sleep‐related parameters referred to 1 month before diagnosis and 1 week before the questionnaire. Multinomial logistic regression models were fitted to compute crude and adjusted odds ratios and 95% confidence intervals (95% CIs). Compared to the pre‐infection period, those with probable post‐COVID‐19 condition reported a greater decrease in hours of sleep, had a 2.60 (95% CI 2.02–3.34) higher adjusted odds of perceiving their sleep quality as worsened and experienced a significant increase in number of days with sleeping disturbances as defined according to multiple items. The association between post‐COVID‐19 condition and indicators of poor sleep health requires special attention from healthcare professionals and services. It is essential that appropriate multidisciplinary care is provided to mitigate the physical, psychological, social, and professional impact of sleeping problems in these already burdened patients.

neurosciences,clinical neurology
Melanoma of the penis and the urethra: 2 case reports and review of the literature.

R. Bracken,A. Diokno

DOI: https://doi.org/10.1097/00006534-197411000-00045

1974-11-01

Abstract:

RECENT ADVANCES IN RADIATION BIOLOGY.

Pre-existing sleep problems as a predictor of post-acute sequelae of COVID-19

Attributes and predictors of long COVID

Cytotoxic cardenolides from woods of Euonymus alata.

Characterizing long COVID in an international cohort: 7 months of symptoms and their impact

Sleep disorder syndromes of post-acute sequelae of SARS-CoV-2 (PASC) / Long Covid

Symptoms and risk factors for long COVID in non-hospitalized adults

The association of insomnia with long COVID: An international collaborative study (ICOSS-II)

Sleep and memory complaints in long COVID: an insight into clustered psychological phenotypes

Highly Sensitive Detection of Bisphenol A by NanoAptamer Assay with Truncated Aptamer.

Prevalence and associations of insomnia after COVID-19 infection

Histiocytosis X and renal insufficiency.

1136 Sleep Disorders in Children and Adolescents with Long COVID

Studying the Effect of Long COVID-19 Infection on Sleep Quality Using Wearable Health Devices: Observational Study

Sleep Disorders in Patients after COVID-19

Long COVID symptoms and sleep problems: a population-based study

Long COVID prevalence and impact on quality of life 2 years after acute COVID-19

1135 Predictors of Post-COVID Clinical and Cognitive Consequences

Sleep and Daytime Problems During the COVID-19 Pandemic and Effects of Coronavirus Infection, Confinement and Financial Suffering: a Multinational Survey Using a Harmonised Questionnaire

The association between probable post‐COVID‐19 condition and sleep‐related parameters: a longitudinal study of non‐hospitalised patients

Melanoma of the penis and the urethra: 2 case reports and review of the literature.